dnl151
Small moleculeexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Nov 16, 2017 (NCT04557800)
Timeline
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06602193 | Phase 2 | Oct 24, 2024 | Biogen, Denali Therapeutics Inc. |
| NCT06264440 | Phase 1 | Feb 12, 2024 | Biogen |
| NCT05418673 | Phase 3 | Aug 26, 2022 | Biogen, Denali Therapeutics Inc. |
| NCT05348785 | Phase 2 | Apr 19, 2022 | Biogen, Denali Therapeutics Inc. |
| NCT05229562 | Phase 1 | Feb 17, 2022 | Biogen |
| NCT05119790 | Phase 1 | Aug 27, 2021 | Biogen, Denali Therapeutics Inc. |
| NCT05005338 | Phase 1 | Jul 28, 2021 | Biogen, Denali Therapeutics Inc. |
| NCT04056689 | Phase 1 | Jul 23, 2019 | Denali Therapeutics Inc. |
| NCT04557800 | Phase 1 | Nov 16, 2017 | Denali Therapeutics Inc. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biogen | For profit | 7 | 6 | 3 | 2021 |
| Denali Therapeutics Inc. | For profit | 7 | 3 | 3 | 2017 |
2 organizations
Page 1 / 1